The selective tyrosine kinase inhibitor Imatinib can block this kinase activity by occupying ATP binding site of Bcr/Abl and inhibit CML cell growth effectively [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.